BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ollmann Saphire E. A Vaccine against Ebola Virus. Cell 2020;181:6. [PMID: 32243796 DOI: 10.1016/j.cell.2020.03.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Tsakiri M, Naziris N, Demetzos C. Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. Int J Pharm 2021;610:121212. [PMID: 34687816 DOI: 10.1016/j.ijpharm.2021.121212] [Reference Citation Analysis]
2 Liu G, Cao W, Salawudeen A, Zhu W, Emeterio K, Safronetz D, Banadyga L. Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector. Pathogens 2021;10:1092. [PMID: 34578125 DOI: 10.3390/pathogens10091092] [Reference Citation Analysis]
3 Galindo I, Garaigorta U, Lasala F, Cuesta-Geijo MA, Bueno P, Gil C, Delgado R, Gastaminza P, Alonso C. Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses. Antiviral Res 2021;186:104990. [PMID: 33249093 DOI: 10.1016/j.antiviral.2020.104990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
4 Jain S, Khaiboullina SF, Baranwal M. Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. Pathogens 2020;9:E850. [PMID: 33080902 DOI: 10.3390/pathogens9100850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Butkovich N, Li E, Ramirez A, Burkhardt AM, Wang SW. Advancements in protein nanoparticle vaccine platforms to combat infectious disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1681. [PMID: 33164326 DOI: 10.1002/wnan.1681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Vasudevan K, Thirumal Kumar D, Udhaya Kumar S, Saleem A, Nagasundaram N, Siva R, Tayubi IA, George Priya Doss C, Zayed H. A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease. Curr Opin Pharmacol 2021;61:28-35. [PMID: 34563987 DOI: 10.1016/j.coph.2021.08.015] [Reference Citation Analysis]
7 Warren TK, Kane CD, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Steffens J, Gomba L, Weidner JM, Norris S, Zeng X, Bannister R, Cihlar T, Bavari S, Porter DP, Iversen PL. Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. Sci Rep 2021;11:19458. [PMID: 34593911 DOI: 10.1038/s41598-021-98971-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vangelista L, Secchi M. Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. Front Mol Biosci 2020;7:226. [PMID: 33033717 DOI: 10.3389/fmolb.2020.00226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines 2022;7:75. [PMID: 35787629 DOI: 10.1038/s41541-022-00503-y] [Reference Citation Analysis]
10 Jonsson-Schmunk K, Ghose R, Croyle MA. Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A. Expert Rev Vaccines 2021;20:623-34. [PMID: 33666138 DOI: 10.1080/14760584.2021.1899818] [Reference Citation Analysis]
11 Morales-Tenorio M, Ginex T, Cuesta-Geijo MÁ, Campillo NE, Muñoz-Fontela C, Alonso C, Delgado R, Gil C. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. Eur J Med Chem 2021;223:113654. [PMID: 34175537 DOI: 10.1016/j.ejmech.2021.113654] [Reference Citation Analysis]
12 Xu Z, Patel A, Tursi NJ, Zhu X, Muthumani K, Kulp DW, Weiner DB. Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Front Med Technol 2020;2:571030. [DOI: 10.3389/fmedt.2020.571030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
13 Furuse Y. [Epidemiology of Viral Hemorrhagic Fever in Africa]. Uirusu 2021;71:11-8. [PMID: 35526990 DOI: 10.2222/jsv.71.11] [Reference Citation Analysis]
14 Ghosh S, Saha A, Samanta S, Saha RP. Genome structure and genetic diversity in the Ebola virus. Curr Opin Pharmacol 2021;60:83-90. [PMID: 34364102 DOI: 10.1016/j.coph.2021.06.010] [Reference Citation Analysis]
15 Lasala F, García-Rubia A, Requena C, Galindo I, Cuesta-Geijo MA, García-Dorival I, Bueno P, Labiod N, Luczkowiak J, Martinez A, Campillo NE, Alonso C, Delgado R, Gil C. Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Res 2021;186:105011. [PMID: 33428961 DOI: 10.1016/j.antiviral.2021.105011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Han S, Li H, Chen W, Yang L, Tong X, Zuo J, Hu Y. Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold. Eur J Med Chem 2022;240:114608. [PMID: 35872393 DOI: 10.1016/j.ejmech.2022.114608] [Reference Citation Analysis]
17 Lundstrom K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses 2020;12:E1324. [PMID: 33218001 DOI: 10.3390/v12111324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
18 Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. Viruses 2021;13:317. [PMID: 33669550 DOI: 10.3390/v13020317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
19 Yang B, Yang KD. Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention. Front Immunol 2021;12:690976. [PMID: 34335596 DOI: 10.3389/fimmu.2021.690976] [Reference Citation Analysis]
20 Imre G, Krähling V, Eichler M, Trautmann S, Ferreirós N, Aman MJ, Kashanchi F, Rajalingam K, Pöhlmann S, Becker S, Meyer Zu Heringdorf D, Pfeilschifter J. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. iScience 2021;24:102266. [PMID: 33817572 DOI: 10.1016/j.isci.2021.102266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Diakou KI, Mitsis T, Pierouli K, Papakonstantinou E, Bongcam-Rudloff E, Wayengera M, Vlachakis D. Ebola Virus Disease and Current Therapeutic Strategies: A Review. Adv Exp Med Biol 2021;1339:131-7. [PMID: 35023100 DOI: 10.1007/978-3-030-78787-5_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Valle C, Martin B, Ferron F, Roig-Zamboni V, Desmyter A, Debart F, Vasseur JJ, Canard B, Coutard B, Decroly E. First insights into the structural features of Ebola virus methyltransferase activities. Nucleic Acids Res 2021;49:1737-48. [PMID: 33503246 DOI: 10.1093/nar/gkaa1276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Hochdorfer D, Businger R, Hotter D, Seifried C, Solzin J. Automated, label-free TCID50 assay to determine the infectious titer of virus-based therapeutics. J Virol Methods 2022;299:114318. [PMID: 34626683 DOI: 10.1016/j.jviromet.2021.114318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhu W, Liu G, Cao W, He S, Leung A, Ströher U, Fairchild MJ, Nichols R, Crowell J, Fusco J, Banadyga L. A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease. Vaccines 2022;10:1004. [DOI: 10.3390/vaccines10071004] [Reference Citation Analysis]
25 Corona A, Fanunza E, Salata C, Morwitzer MJ, Distinto S, Zinzula L, Sanna C, Frau A, Daino GL, Quartu M, Taglialatela-scafati O, Rigano D, Reid S, Mirazimi A, Tramontano E. Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105251] [Reference Citation Analysis]
26 Milligan JC, Davis CW, Yu X, Ilinykh PA, Huang K, Halfmann PJ, Cross RW, Borisevich V, Agans KN, Geisbert JB, Chennareddy C, Goff AJ, Piper AE, Hui S, Shaffer KCL, Buck T, Heinrich ML, Branco LM, Crozier I, Holbrook MR, Kuhn JH, Kawaoka Y, Glass PJ, Bukreyev A, Geisbert TW, Worwa G, Ahmed R, Saphire EO. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 2022;185:995-1007.e18. [PMID: 35303429 DOI: 10.1016/j.cell.2022.02.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
27 Liu Y, Sun B, Pan J, Feng Y, Ye W, Xu J, Lan M, Sun H, Zhang X, Sun Y, Yang S, Shi J, Zhang F, Cheng L, Jiang D, Yang K. Construction and evaluation of DNA vaccine encoding Ebola virus glycoprotein fused with lysosome-associated membrane protein. Antiviral Res 2021;193:105141. [PMID: 34274417 DOI: 10.1016/j.antiviral.2021.105141] [Reference Citation Analysis]
28 Jain S, Martynova E, Rizvanov A, Khaiboullina S, Baranwal M. Structural and Functional Aspects of Ebola Virus Proteins. Pathogens 2021;10:1330. [PMID: 34684279 DOI: 10.3390/pathogens10101330] [Reference Citation Analysis]
29 Schiffman Z, Liu G, Cao W, Zhu W, Emeterio K, Qiu X, Banadyga L. The Ferret as a Model for Filovirus Pathogenesis and Countermeasure Evaluation. ILAR J 2021:ilab011. [PMID: 33951727 DOI: 10.1093/ilar/ilab011] [Reference Citation Analysis]